Canprobe

Canprobe is a Canadian joint venture between the University Health Network (UHN) and the Centre for Probe Development and Commercialization (CPDC) dedicated to the development and commercialization of radiopharmaceuticals. The company operates out of Toronto, utilizing high-standard GMP manufacturing facilities to produce targeted imaging and therapeutic agents for oncology. Their core activities involve the translation of radiochemistry innovations into clinical-grade products, specifically focusing on prostate cancer and neuroendocrine tumors. Canprobe serves as a strategic partner for global pharmaceutical companies looking to manufacture and distribute radiopharmaceuticals within the Canadian market. The organization bridges the gap between academic discovery and commercial clinical application through specialized expertise in regulatory affairs and radiochemistry.